currently this is your benchmark, unfortunately they aren't quite there
"In a planned secondary analysis, the proportion of patients receiving GEN-003 who were lesion-free at six months after dosing ranged from approximately 30 to 50 percent, similar to results reported in clinical trials with oral antiviral therapies"
bodes well for Frazer though.
How far "behind" Genocea are we?, page-2
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.73 |
Change
-0.270(1.93%) |
Mkt cap ! $295.9M | |||
| Open | High | Low | Value | Volume |
| $14.05 | $14.05 | $13.73 | $47.18K | 3.405K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 49 | $13.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.88 | 268 | 1 |
View Market Depth
| Last trade - 11.42am 08/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |